Who We Are
We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.
Our Technology
DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells.
Experienced Leadership
Helix is led by an experienced Management team with excellent pharmaceutical development expertise and proven business skills.
The group is committed to developing novel medicines through DOS47 platform technology.
Praveen Varshney
Management Team
Jacek Antas
Chief Executive Officer
Dr. Srikanth Sola
Chief Strategy Officer
Praveen Varshney
Chief Financial Officer
Dr. Thomas Mehrling
Dr. Thomas Mehrling
Medical Adviser
Christof Bohler
Christof Boehler
Chief Business Development
Board of Directors
Jacek Antas
Chairman of the Board
Malgorzata Laube
Malgorzata Laube
Director
Jerzy Leszczynski
Jerzy Leszczynski
Director
Janusz Grabski
Janusz Grabski
Director, Chair of Audit Committee
Scientific Team
Kim Gaspar, Ph.D
Kim Gaspar, PhD
Director Quality Assurance
Brenda Lee
Brenda Lee, M.Sc.
Director Clinical Operations
Dr. Praveen Kumar
Praveen Kumar, PhD
V.P. Drug Development